title: Decreased cytotoxic potential of fresh and recombinant interleukin 2-cultured large granular lymphocytes in childhood acute lymphoblastic leukemia.
abstract: Cytotoxic potential (cytotoxic efficiency and binding affinity) of large granular lymphocytes (LGL) in childhood acute lymphoblastic leukemia (ALL) patients was calculated by Michaelis-Menten's kinetic equation. Cytotoxic efficiency (Vmax) of fresh or 3-day recombinant interleukin 2 (IL-2)-cultured LGL, not of similarly cultured T cells, in on-therapy ALL patients was decreased (31% in fresh LGL, P less than 0.05 and 28% in cultured LGL, P less than 0.01) as compared with that in controls, although the binding affinity (Km) of these cells were not decreased. The cytotoxic efficiency and the binding affinity of IL-2-cultured LGL in off-therapy ALL patients was not decreased. These data indicate that the cytotoxic potential of LGL was selectively decreased in on-therapy ALL patients due to the impairment in the post-binding cytotoxic process, not due to the decrease in the binding affinity.
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: Y
authors.initials: Y
authors.lastname: Miyagawa
authors.forename: A
authors.initials: A
authors.lastname: Komiyama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D002478:Cells, Cultured; D002648:Child; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004261:DNA Replication / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone